MaxCyte to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

MaxCyte (Nasdaq: MXCT; LSE: MXCT), a cell-engineering platform technology company, has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Stifel 2024 Healthcare Conference on November 18th at 10:55 AM ET and the Stephens Annual Investment Conference on November 19th at 3:00 PM CT. Interested parties can access live and archived webcasts of both events through MaxCyte's investor relations website.

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences.

• Stifel 2024 Healthcare Conference
  Fireside Chat on Monday, November 18^th at 10:55 AM ET
  

• Stephens Annual Investment Conference
  Fireside Chat on Tuesday, November 19^th at 3:00 PM CT

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

US Media Relations
Spectrum Science
Jordan Vines+1 540-629-3137
jvines@spectrumscience.com

Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com

FAQ

When is MaxCyte (MXCT) presenting at the Stifel 2024 Healthcare Conference?

MaxCyte (MXCT) will present at the Stifel 2024 Healthcare Conference on Monday, November 18th at 10:55 AM ET.

What time is MaxCyte's (MXCT) fireside chat at the Stephens Annual Investment Conference?

MaxCyte's fireside chat at the Stephens Annual Investment Conference is scheduled for Tuesday, November 19th at 3:00 PM CT.

Where can I watch MaxCyte's (MXCT) investor conference presentations?

Live and archived webcasts of MaxCyte's presentations can be accessed through the 'Events' section of their investor relations website at investors.maxcyte.com.

Which investor conferences is MaxCyte (MXCT) attending in November 2024?

MaxCyte is attending the Stifel 2024 Healthcare Conference and the Stephens Annual Investment Conference in November 2024.